SLAMF7 Polyclonal Antibody

SLAMF7

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform1mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway (PubMed:11698418). Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K (PubMed:16339536). In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Acts also inhibitory in T-cells (By similarity). May play a role in lymphocyte adhesion (PubMed:11802771). In LPS-activated monocytes negatively regulates production of proinflammatory cytokines (PubMed:23695528).

PBS with 0.05% NaN3 and 40% Glycerol,pH7.4

2.5 mg/mL

Unconjugated

IHC 1:30-1:150, ELISA 1:5000-1:10000

Fusion protein of human SLAMF7

Antigen affinity purification

19A;19A24 protein;CD 319;CD2 like receptor activating cytotoxic cells;CD2 subset 1;CD319 ;CD319 antigen;CRACC ;CS1 ;Membrane protein FOAP 12;Novel Ly9 ;Novel LY9 (lymphocyte antigen 9) like protein;Protein 19A;SLAM family member 7;SLAMF 7

Q9NQ25